I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| ciliated cell | 8 studies | 26% ± 8% | |
| type I pneumocyte | 4 studies | 25% ± 6% | |
| GABAergic neuron | 3 studies | 43% ± 5% | |
| glutamatergic neuron | 3 studies | 59% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 8 studies | 26% ± 8% | |
| type I pneumocyte | 4 studies | 25% ± 6% | |
| GABAergic neuron | 3 studies | 43% ± 5% | |
| glutamatergic neuron | 3 studies | 59% ± 7% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 3 studies | 39% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 94% | 997.95 | 230 / 245 | 83% | 19.90 | 415 / 502 |
| breast | 98% | 1415.04 | 452 / 459 | 75% | 93.33 | 843 / 1118 |
| lung | 98% | 885.13 | 565 / 578 | 68% | 20.05 | 785 / 1155 |
| esophagus | 83% | 762.82 | 1202 / 1445 | 57% | 13.47 | 105 / 183 |
| thymus | 97% | 632.33 | 632 / 653 | 36% | 4.42 | 218 / 605 |
| stomach | 83% | 1745.26 | 298 / 359 | 47% | 11.42 | 135 / 286 |
| uterus | 64% | 301.58 | 108 / 170 | 65% | 25.60 | 298 / 459 |
| kidney | 70% | 300.97 | 62 / 89 | 37% | 3.63 | 336 / 901 |
| bladder | 62% | 254.19 | 13 / 21 | 44% | 10.76 | 223 / 504 |
| ovary | 18% | 72.66 | 32 / 180 | 88% | 29.24 | 377 / 430 |
| brain | 86% | 722.50 | 2264 / 2642 | 19% | 2.19 | 132 / 705 |
| blood vessel | 100% | 2351.23 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 99% | 1208.57 | 1187 / 1204 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 80% | 45.04 | 36 / 45 |
| intestine | 24% | 79.81 | 233 / 966 | 55% | 14.07 | 290 / 527 |
| skin | 69% | 535.41 | 1250 / 1809 | 3% | 1.08 | 15 / 472 |
| heart | 71% | 444.55 | 613 / 861 | 0% | 0 | 0 / 0 |
| muscle | 69% | 274.18 | 556 / 803 | 0% | 0 | 0 / 0 |
| pancreas | 13% | 39.73 | 43 / 328 | 47% | 6.89 | 83 / 178 |
| liver | 33% | 120.81 | 74 / 226 | 26% | 3.83 | 105 / 406 |
| adrenal gland | 19% | 72.62 | 50 / 258 | 9% | 0.91 | 21 / 230 |
| eye | 0% | 0 | 0 / 0 | 5% | 0.39 | 4 / 80 |
| spleen | 1% | 2.07 | 2 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 1.60 | 2 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006629 | Biological process | lipid metabolic process |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0062189 | Molecular function | anandamide 14,15 epoxidase activity |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0020037 | Molecular function | heme binding |
| Gene name | CYP4X1 |
| Protein name | Cytochrome P450 4X1 (EC 1.14.14.-) (CYPIVX1) |
| Synonyms | UNQ1929/PRO4404 |
| Description | FUNCTION: A cytochrome P450 monooxygenase that selectively catalyzes the epoxidation of the last double bond of the arachidonoyl moiety of anandamide, potentially modulating endocannabinoid signaling. Has no hydroxylase activity toward various fatty acids, steroids and prostaglandins. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). . |
| Accessions | ENST00000371901.4 [Q8N118-1] Q8N118 |
